In the quest to develop more accessible weight loss solutions, pharmaceutical companies are racing to introduce an oral version of the latest class of weight loss drugs. At the 2023 American Diabetes Association Scientific Sessions, two clinical trials showcased significant progress in creating a daily pill for weight loss, potentially offering a more convenient option than weekly injections. Drugs like Eli Lilly's Mounjaro and Novo Nordisk's Ozempic and Wegovy have gained immense popularity for their effectiveness in promoting weight loss but are currently administered through injections. Novo Nordisk presented promising findings regarding an oral version of semaglutide, the active ingredient in Ozempic and Wegovy. Participants in a phase 3 clinical trial experienced an average weight loss of 15% over 68 weeks, matching the results seen with the injectable version.

This development has been hailed as a game-changer by experts, as many individuals prefer taking medication in pill form rather than injections due to needle aversion. Dr. Mico Guevarra, leading the research on oral semaglutide for Novo Nordisk, emphasized the importance of providing individuals with diverse treatment options tailored to their preferences and goals. Although an oral weight loss drug is not expected to hit the market in 2023, it signifies a significant step towards expanding choices and accessibility. While some have noted the potential for more severe side effects compared to injections, particularly increased nausea with oral semaglutide (Rybelsus), the development of this oral option holds promise for revolutionizing weight loss treatments.

Original article here.